In addition, NK cells have been shown to kill other MS-relevant cell types, such as microglial cells by use of the NKG2D as well as the NKp46 receptor pathways (100), autologous immature myeloid cells via NKp30, NKp46 and DNAM-1 (101–103) and activated macrophages through NKG2D as well (104). Here, CD226 is linked to myeloid sarcoma.